Stockscreener 앱 받기
12.01
1.64%
-0.20
Omeros Corporation 주식(OMER)의 최신 뉴스
Omeros Shares Face Headwinds Amid Mixed Signals - AD HOC NEWS
Omeros (NASDAQ:OMER) Shares Down 5.8% Following Insider Selling - MarketBeat
Omeros (NASDAQ:OMER) CAO Sells 30,000 Shares - MarketBeat
Omeros (OMER) Price Target Increased by 29.70% to 44.54 - Nasdaq
Omeros VP Borges sells $750k in shares By Investing.com - Investing.com Nigeria
Omeros VP Borges sells $750k in shares - Investing.com
Omeros Corp Sells Immune-System Drug To Novo Nordisk In $2.1B Deal — Retail Shifts Focus To Narsoplimab FDA Call - MSN
HC Wainwright Has Bearish Outlook for Omeros FY2026 Earnings - MarketBeat
Why did Omeros stock jump 5% in after-hours trading today? - MSN
Will Omeros Corporation stock see insider buyingRecovery Day Options & size guide reminders to avoid returns - Улправда
Omeros Details Yarcomlia U.S. Launch After FDA Approval, Pricing and Supply Outlook in Focus - MarketBeat
Omeros (NASDAQ:OMER) Stock Rating Lowered by Wall Street Zen - MarketBeat
Omeros stock garners high retail attention ahead of FDA verdict for life-saving drug - MSN
What is HC Wainwright's Forecast for Omeros Q1 Earnings? - MarketBeat
Fundamentals Check: Will Omeros Corporation stock see insider buyingMarket Growth Report & Daily Stock Momentum Reports - Улправда
Why Omeros Corporation stock could benefit from AI revolutionJuly 2025 Technicals & Growth-Oriented Investment Plans - Улправда
Why retail investors pile into Omeros Corporation stock2025 Sector Review & Technical Entry and Exit Tips - ulpravda.ru
Omeros (NASDAQ:OMER) Trading Up 10.3% on Analyst Upgrade - MarketBeat
Omeros stock rises in premarket after $36,000-a-vial Yartemlea price is set - TechStock²
OMER: HC Wainwright & Co. Raises Price Target to $40 with Buy Ra - GuruFocus
OMER's Rating Maintained as 'Buy' with $36 Price Target by Analyst | OMER Stock News - GuruFocus
Balanced Risk/Reward and Gradual Yartemlea Ramp Justify Hold Rating on Omeros - TipRanks
Omeros (NASDAQ:OMER) Price Target Raised to $40.00 - MarketBeat
Omeros (NASDAQ:OMER) Earns Buy Rating from D. Boral Capital - MarketBeat
Omeros Stock Enters Commercial Phase with Key Drug Launch - AD HOC NEWS
Omeros prices transplant complication drug at $36,000 per dose - whbl.com
Why Did Omeros Stock Jump 5% In After-Hours Trading Today? - Stocktwits
Is Omeros Corporation stock attractive for income investorsGrowth Stock Opportunities & Affordable Investment Portfolio - ulpravda.ru
Can Omeros Corporation stock deliver surprise earnings beatDay Trading Setups & Outstanding Growth Portfolio - ulpravda.ru
Omeros Corporation (OMER): Novo Nordisk deal creating buzz - MSN
Omeros (NASDAQ:OMER) Trading Down 6%Should You Sell? - MarketBeat
Assessing Omeros (OMER) Valuation After YARTEMLEA’s FDA Approval And Planned US Launch - simplywall.st
Will FDA Approval of YARTEMLEA in TA-TMA Redefine Omeros' (OMER) Commercial Trajectory? - simplywall.st
Omeros (NASDAQ:OMER) Sets New 12-Month HighStill a Buy? - MarketBeat
Omeros Corporation (NASDAQ:OMER) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Omeros stock jumps premarket after FDA approves first drug for rare transplant complication — retail sees big upside - MSN
Will Omeros Corporation stock deliver better than expected guidanceGrowth Stock Opportunities & Ride the Wave of Market-Beating Growth - bollywoodhelpline.com
Omeros (NASDAQ:OMER) Trading Up 4.6%Here's Why - MarketBeat
Best Pharmaceutical Stocks To Watch TodayDecember 24th - MarketBeat
Retail’s Christmas Eve watchlist: Omeros, Nike, Citi, Dynavax and Agios spark most market chatter - MSN
Commit To Buy Omeros At $10, Earn 26.6% Annualized Using Options - Nasdaq
Omeros Gets FDA Approval for YARTEMLEA as First Therapy for TA-TMA - Yahoo Finance
Omeros Corp Stock Soars A Whopping 136% Pre-Market After Novo Nordisk Agrees To Buy Its Drug Candidate For Blood Disorder - MSN
Omeros Corp Announces FDA Approval of YARTEMLEA for TA-TMA - TradingView — Track All Markets
Omeros (NASDAQ: OMER) secures FDA nod for YARTEMLEA in TA-TMA - Stock Titan
Omeros: Why The Novo Nordisk Deal Is More Important Than FDA Approval (Rating Upgrade) - Seeking Alpha
FDA Clears First Therapy for Transplant Associated Thrombotic Microangiopathy - prismedia.ai
Omeros to resume trading at 9:50 AM ET - MSN
D Boral Capital notes Omeros’ YARTEMLEA FDA win, maintains buy rating - MSN
Why Omeros stock skyrocketed today - MSN
Omeros Announces New Date for YARTEMLEA® Approval Conference Call - Caledonian Record
4.73%
0.92%
자본화:
|
볼륨(24시간):